Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionVir Biotechnology Inc. Common Stock (VIR)
Fair value
Not available
ACCE price target
$10.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $10.57 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
72
out of 100
Analysts
100% buy
9 covering
P/E
0.0x
forward 4.3x
1-year return
+82.9%
Dividend yield
0.00%
Vir Biotechnology Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Vir Biotechnology develops antiviral and immunology antibodies, with its commercial focus on hepatitis delta and influenza programs built on its platform for discovering monoclonal antibodies. The case rests on the pipeline rather than current sales: the revenue line is a collaboration and milestone story, and the reported 19,582% growth rate reflects a very small prior-year base, so it should not be read as a durable trend. Near-term catalysts are clinical readouts in chronic hepatitis delta and related programs, where a positive data set would matter more to the valuation than any single quarter's revenue. The stock screens cheaply on forward earnings at 4.3 times, and operating margin of 30.8% against a negative gross margin of -59.4% suggests the reported operating profit is driven by one-off collaboration income and not by a repeatable product business, which is the first thing to pressure-test. A deeper look should focus on the durability of partnership cash, the trial timelines for hepatitis delta, and how much of the market cap is backed by the pipeline versus cash on hand.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Cash burn outpaces earnings
Free cash flow was -$396.6M while net margin is -83.0% and gross margin is -59.4%. Reported operating margin of +30.8% does not square with negative gross margin, so the profit line needs checking before relying on it.
moderate
Revenue spike is one-off
Revenue grew 19,582.5% year over year but QoQ is -100.0% and the 5-year revenue CAGR is -2.1%. The jump looks like a single lumpy period, not a durable trend.
moderate
Insiders selling, no buys
Insiders disclosed $2.67M in sales and $0.00M in buys across the last 10 filings. Short interest is 9.0% of float.
AI research notes
AI-assisted·How I use AIWritten Oct 20, 2026 · figures from 2026-10-20 · prices to Oct 23, 2026
Why it could do well
Nine of nine analysts rate the stock Buy or Strong Buy, and their mean price target sits well above the current share price.
Debt is modest against equity, with debt to equity at 0.24, so the balance sheet is not the main pressure point.
The stock trades at a forward P/E of 4.3x, which looks cheap if earnings expectations hold up.
Why it could disappoint
Free cash flow over the last twelve months was negative $397M, meaning the business is still burning cash.
Latest earnings per share came in 43.4% below expectations, with 0.47 reported against 0.83 expected.
Net margin of -83.0% and a -23.5% free cash flow yield show the company is losing money on its revenue.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where VIR's valuation models land
Price
$10.57
Model fair valueConfidence: low
about $14.42
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores